Black Titan Corporation (BTTC) Next Earnings Date & Expected ±12.5% Move

$0.32 -8.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.31

Black Titan Corporation (BTTC) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $5.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BTTC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BTTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Black Titan Corporation (NASDAQ: BTTC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.32 (-8.05% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BTTC ranks #596 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BTTC compare to CELZ and LIMN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BTTC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CELZ (Creative Medical Technology Holdings Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $5.2M) and LIMN (Liminatus Pharma Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.9M). Among the 5-stock peer group, BTTC leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BTTC?
▼

Per BTTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-07-31, CIK 0002034400), Black Titan Corporation generated $0 in revenue, -$163.2K in net income, and -$143.2K in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.31 (-1.64%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510038
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Cash (10)Whales (6)SEC (10)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$11 Bull$0 Base$0 Bear
📬 FREE BTTC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BTTC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY BTTC SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+10/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
46
Grade D$0.49-28.6% Next Q
Q2 (-2Q)
43
Grade D$0.35+2.9% Next Q
Q3 (-1Q)
41
Grade D$0.36-11.1% Next Q
Current
38
Grade D-$0.32-7.8% Hist 90D α
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BTTC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BTTC currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.45) and Max Pain ($0.34) forces dealer call-delta covering toward $10.55.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BTTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BTTC Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
NEXT EST. WINDOW: Jan 28, 2027 (~86 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.04 Expected Swing
$1.00 (-12.5%)Spot $0.32$0.36 (+12.5%)
MODEL EARNINGS SETUP GAUGE

BTTC Quantitative Pre-Earnings Setup: 38/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (38/100)Model Risk Weight (62/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-07-31$0-$163.2K-$143.2K52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BTTC)

  • ✓Walkthrough of BTTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BTTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -73.98%▼ DESCENDING CHANNEL
2026-11-02O $0.34H $0.35L $0.32C $0.32VOL 183.4K
RES: $0.84SUP: $0.16SMA50: $0.45SMA200: $1.03
$2.83$2.15$1.47$0.79$0.11RES $0.84SUP $0.16$0.322026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BTTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BTTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BTTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BTTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BTTC)

Health Care Rank #596 of 1016 ⚔️ CELZ vs BTTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BTTC vs. CELZ, LIMN, CRIS, PMCB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Black Titan Corporation (BTTC) ranks #596 by composite RQD confidence (38/100, grade D-) and #942 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, BTTC leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BTTC ACTIVE
Black Titan Corporation
D- 38/100 — — — -8.05% $5.3M Benchmark Subject
CELZ
Creative Medical Technology Holdings Inc.
E 20/100 — 63.4% -35.0% -3.45% $5.2M /celz-vs-bttc →
LIMN
Liminatus Pharma Inc. (Class A)
E 34/100 — — -35.0% -2.59% $3.9M /limn-vs-bttc →
CRIS
Curis Inc.
E 27/100 — — -35.0% +9.39% $3.7M /cris-vs-bttc →
PMCB
PharmaCyte Biotech Inc.
D- 35/100 — — -30.2% -9.03% $3.6M /pmcb-vs-bttc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-07-31 • CIK 0002034400

In its most recent audited fiscal period (FY2025, filed 2025-07-31), Black Titan Corporation (BTTC) reported GAAP revenue of $0 , GAAP net income of -$163.2K, operating cash flow of -$143.2K, and free cash flow of -$143.2K . On the balance sheet, BTTC closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-07-31 $0 -$163.2K -$143.2K -$143.2K — —

3. BTTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BTTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Black Titan Corporation (NASDAQ: BTTC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.32 (-8.05% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BTTC ranks #596 in composite RQD confidence.

How does BTTC compare to CELZ and LIMN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BTTC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CELZ (Creative Medical Technology Holdings Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $5.2M) and LIMN (Liminatus Pharma Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.9M). Among the 5-stock peer group, BTTC leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BTTC?

Per BTTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-07-31, CIK 0002034400), Black Titan Corporation generated $0 in revenue, -$163.2K in net income, and -$143.2K in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BTTC trading relative to its 50-day, 200-day, and 52-week technical levels?

BTTC last traded at $0.32 (-8.05% on volume of 208,378 shares), positioning the stock -28.89% below its 50-day simple moving average ($0.45) and -68.93% below its 200-day simple moving average ($1.03). Across its 52-week range of $0.32 to $10.05, BTTC sits at the 0.0% percentile with a 14-day RSI of 41.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.36).

BTTC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is BTTC's next earnings date?

Based on SEC filing cadence, Black Titan Corporation (BTTC)'s next quarterly reporting window is estimated around Jan 28, 2027.

How much is BTTC stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for BTTC, spanning a range between $1 and $0.36.

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BTTC — Black Titan Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:20:29Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BTTC scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars break down as follows:

  • Fundamental Cash Engine: 10 / 20. The rating cites ROIC of 0% and an FCF yield of -2.73%. For a prospective investor, this means the business is not currently generating returns on invested capital or positive free cash flow, so the stock's value rests on future earnings that the source data does not evidence.
  • Whale 13F Flow: 6 / 20. The rating reflects institutional accumulation and options positioning. Because the holders section is empty in the source data, the specific institutional signal behind this score cannot be independently verified here.
  • Insider Conviction: 5 / 20. The rating reflects SEC Form 4 and Congressional PTR cluster flow. Insider flow is weighted lightly, and the detailed trades are not itemized in the source data.
  • Macro Regime Fit: 7 / 20. The rating cites a beta of 1.0 and sector sensitivity. A beta of 1.0 indicates market-level volatility relative to the broader market, but the score suggests limited alignment with the current macro regime.
  • Forensic Balance Sheet: 10 / 20. The rating cites an Altman Z of 2.5, a Piotroski F of 1/9, and Debt/Equity of 0.5. The Piotroski reading of 1/9 is a notable weakness in financial-health screening, while the Altman and leverage figures are moderate.

Taken together, the score points to a stock where upside depends on a turnaround in cash generation that is not yet visible in the reported figures. The sub-$1 price, a 52-week range of $0.32 to $10.05, and a $5.3M market capitalization describe a highly speculative and illiquid-profile equity. Prospective investors should treat the rating as a warning on balance-sheet and cash-flow quality rather than as a valuation signal.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025 (filed 2025-07-31)$0.0M$0.0M$-0.2MN/A$-0.1MN/AN/A

Per the SEC financials, FY 2025 reported zero revenue and zero operating income, a net loss of $-0.2M, and free cash flow of $-0.1M. Gross, operating, and net margins are each recorded as 0% in the market data, and ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 1/9, and Debt/Equity is 0.5. The reported cash and debt balances are not available in source data, so the balance-sheet posture can only be characterized through the rating's forensic pillar.

Recent Catalysts & News Wire Analysis

The news wire contains five items, all tagged with BTTC as the related symbol. Four are Market Wire items flagged YELLOW, consisting of Yahoo! Finance Canada seasonal-chart and quote pages whose headlines reference other companies (Phunware, Youxin Technology, Ahasolar Technologies, AXIL Brands). Their summaries are generic and contain no company-specific operating news. One item is a CATALYST flagged GREEN, headlined as Arena Group Holdings (AREN) rising 19% to $1.12 toward a $1.18 resistance level; its summary field references an unrelated domain and it does not describe a BTTC event. The risk watch item is that none of the wire items provide a verifiable BTTC-specific fundamental catalyst. The Butterfly Supply-Chain Graph reports no supply-chain relationships and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

The Butterfly Supply-Chain Graph lists the supply chain as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies are therefore not available in source data. Sector correlation and second-order bottlenecks cannot be mapped from the provided materials. A prospective investor should note that the absence of mapped links means ripple effects from suppliers, customers, or peer companies cannot be assessed here.

Open Questions

  • What is the company's actual product pipeline and revenue model, given that the source data reports zero revenue in FY 2025?
  • What are the reported cash and debt balances, which are listed as N/A in the financials?
  • Why are FY 2025 net losses reported without a corresponding EPS figure, and what is the share count?
  • What drove the stock's 52-week decline from $10.05 to $0.32, and is there a listing-compliance or going-concern issue behind it?
  • Which institutional holders and insiders are behind the whale and insider pillar scores, since the holders section is empty?

BTTC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Black Titan Corporation (BTTC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BTTC Debate Forum (3) ↓
🟡 MARKET WIRE Yahoo Finance • 286d ago
Early & Accessible Investing

NEW YORK CITY, NEW YORK / ACCESS Newswire / January 20, 2026 / The very concept of an "investment" is being redefined. High barriers to entry are being dismantled by technology, creating a more democratized landscape. Th

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BTTC Bull vs. Bear Conversation Board — What's Your Call at $0.32?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BTTC 🐻 67% BEARISH CONVICTION
1. Pick Your Side on BTTC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.31 (-11.4%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BTTC (D- • RQD 38/100) a Buy at $0.35?

Welcome to the BTTC (Black Titan Corporation) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.29 (-17.1%)
Spot @ $0.35

Pump the brakes on BTTC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BTTC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Black Titan Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.40 (+14.3%)
Spot @ $0.35

BTTC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BTTC, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.35 (52-wk range $0.32 - $10.05), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%